CGON Stock — CG Oncology, Inc.

CG Oncology, Inc. (CGON)

Updated October 16, 2026.

CGON is a Stock. Total return is 61.0% over the past 2.7 years, 0.5 points behind SPY at 61.5%.

CG Oncology is a late-stage clinical biopharmaceutical company developing cretostimogene, an investigational oncolytic immunotherapy for bladder cancer patients, with multiple ongoing phase 2 and phase 3 clinical trials. The company does not currently distribute dividends. This security appeals to investors with high risk tolerance seeking exposure to clinical-stage biotechnology companies.

CGON performance versus SPY

Price and return data through 2026-10-16.

Total return is 61.0% over the past 2.7 years, 0.5 points behind SPY at 61.5%. Over the past year its total return — price change plus distributions reinvested — is 43.0%. Its deepest 1-year drawdown was 27.4%.

CGON key facts

Asset type

Stock

Asset class

Equity

Inception date

01/25/2024

Distribution frequency

None

Last close

$59.85 (as of 2026-10-16)

Market cap

$5,305,126,444

Average volume

1079665.0

Beta

0.28

Payout ratio

0.0%

EPS

$-2.69

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CGON risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 27.4%.

Who may consider CGON — and who may not

It is a weaker fit for investors who need monthly cash flow (CGON does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on CGON

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions